Navigation Links
YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
Date:6/23/2009

than 3,500 patients reported as having been treated with nimotuzumab worldwide to date, no Grade IV incidents of radiation dermatitis have been described, severe rash has not been observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been rare. Nimotuzumab is licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using fentanyl because patients can individually control the analgesia required for their differing intensities of pain. AeroLEF met all endpoints in a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014 ... analyze and research medicinal plants and therapeutic derivatives ... industry, health professionals, and researchers about the challenges ... (Logo: http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The ...
(Date:1/14/2014)... January 14, 2014 iLab Solutions, the leader ... the new Director of Product Strategy. In this role, Michelle ... iLab sub-teams to guide in the development of iLab products. ... the maximum possible benefit to the scientific community by offering ...
(Date:1/14/2014)... Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), ... commercializing innovative therapies addressing major unmet medical needs ... the Notice of Allowance from the United States ... RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. ...
(Date:1/14/2014)... ®, provider of RapidResponse ®, a cloud-based supply chain ... S&OP ) service, is proud to be a gold sponsor ... at the Hilton San Diego Bayfront, January 30 – 31, ... , Director of Supply Chain at Amgen, as she presents ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... , which has promised Milwaukee that it can provide citywide ... reprieve by the Milwaukee Common Council after falling ... give Midwest Fiber until June 7 to hook up the ... The company was to have the area hooked up by ...
... this, about half of all Americans required to do so are scurrying ... in Sunday's Arizona Republic . For a lot of folks like ... back by two days this year, was indeed upon us. And we'd ... of tax laws changed this year. , ,The realization that Tax Day ...
... stuff of legends. Sit in any presentation by one ... PowerPoint slide you'll likely be convinced that the methodology ... itself, and eventually bring about world peace in our ... unique and special. When they are questioned about the ...
Cached Biology Technology:Turbo Tax Online can teach new Web concepts a business lesson 2Turbo Tax Online can teach new Web concepts a business lesson 3With tech implementations, it's NOT the methodology, stupid 2With tech implementations, it's NOT the methodology, stupid 3
(Date:4/23/2014)... and German . ... the difference between sexes depends on one single element of the ... the two sexual chromosomes are X and Y, whereas women have ... the morphological and physiological differences between males and females. , But ... ago, the X and Y were identical, until the Y started ...
(Date:4/23/2014)... is available in French and Spanish ... 23 April 2014Today, the CEC released its Conservation Assessment ... Approach to Conservation, which identifies 29 priority conservation areas ... includes 11 different protected areas in the states of ... diverse arid and semi-arid habitats inhabited by rare and ...
(Date:4/23/2014)... People who have had a stroke, often suffer motor ... a study conducted in Taiwan, that will be published ... but is currently freely available on-line as an unedited ... when one group of stroke victims had their own ... brain and a similar group did not, those who ...
Breaking Biology News(10 mins):Male or female? 2Male or female? 3Conservation priorities released for several protected areas along US-Mexico border 2Conservation priorities released for several protected areas along US-Mexico border 3Autologous stem cell therapy improves motor function in chronic stroke victims 2
... YORK (Feb. 28, 2013) The Democratic Republic of ... Okapi Faunal Reserve (OFR), has declined by 37 percent in ... according to wildlife surveys by WCS and DRC officials. ... DRC continues unabated, the species could be nearly extinguished from ...
... source of great controversyparticularly in Europebut acts of vandalism ... the health and ecological impacts of those crops hard ... for use in GM crop studies could serve as ... crop biotechnology, according to an article published in ...
... 2,778 bees while retracing the muddy steps of a scientist ... than a century ago. Occasionally stung, but considering herself ... guided her field work, the Montana State University ecologist and ... ." "It,s exciting," Burkle said as the Feb. 28 ...
Cached Biology News:Elephants are vanishing from DRC's best-run reserve 2Elephants are vanishing from DRC's best-run reserve 3Elephants are vanishing from DRC's best-run reserve 4Fighting GM crop vandalism with a government-protected research site 2Old records, new bees result in 'Science' paper for MSU ecologist 2Old records, new bees result in 'Science' paper for MSU ecologist 3
... Novagen's HT96 Isothermal Block is an ... hold HT96 plates and to provide efficient ... plate. This new design of the HT96 ... offers an enhanced product design allowing for ...
Umbilical cord blood neutrophils, For immunohistochemistry (IHC)...
...
Adjustable tilt angle 0 to 20 Adjustable speed of 3-25 RPM Load capacity: 2.7 kg (6 lbs.) Ambient temperature range 4C to 65C Low voltage power is supplied by wall mount transformer...
Biology Products: